Article

Ephedrine Sulfate Injection Receives FDA Nod

The FDA recently approved Endo International and Par Pharmaceutical’s new drug application for its 50 mg/ml ephedrine sulfate injection.

The FDA recently approved Endo International and Par Pharmaceutical’s new drug application for its 50 mg/ml ephedrine sulfate injection.

The drug, a parenterally administered pressor agent, is indicated for the treatment of clinically important hypotension in surgery.

Adverse events associated with the use of ephedrine sulfate include nausea, vomiting, and tachycardia. The FDA also warned that the concomitant use of the medication with oxytocic drugs could result in pressor effects, and that repeated administration could lead to tachyphylaxis.

Par Pharmaceuticals plans to launch its 50 mg/ml ephedrine sulfate injection as packaged cartons of 25 single-use vials in February 2017.

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Related Videos
Image credit:  Artur | stock.adobe.com
Cardiovascular disease doctor or cardiologist holding red heart in clinic or hospital exam room office for csr professional medical service, cardiology health care and world heart health day concept - Image credit: Chinnapong | stock.adobe.com
Image credit: AwieDarwis | stock.adobe.com
Image credit: viperagp | stock.adobe.com
Image credit:  kitsawet | stock.adobe.com
Inflammation concept, inflammated human tissues 3d rendering - Image credit: picture-waterfall | stock.adobe.com